Loading people...
Genghis Lloyd-Harris is a Partner at Abingworth, a leading global life sciences venture capital firm. He specializes in identifying, evaluating, and investing in innovative biotechnology and pharmaceutical companies.
He invests in life sciences companies, primarily focusing on novel therapeutics in areas such as oncology, rare diseases, and immunology. His investments span drug discovery, clinical development, and advanced gene therapies.
Genghis Lloyd-Harris works as a Partner at Abingworth, a prominent global life sciences venture capital firm dedicated to investing in healthcare innovation.
Genghis Lloyd-Harris is a Senior Advisor at the transatlantic life sciences investment firm Abingworth LLP in London, United Kingdom. He joined the firm in 2004 after serving as a Managing Director in European Equity Research at Credit Suisse First Boston, where he ranked first in Institutional Investor surveys for three consecutive years. During his three decades in finance and venture capital, he has directed investments across biopharmaceuticals and medical devices, facilitating major exits including the acquisitions of Novexel by AstraZeneca and Algeta by Bayer. He has held board positions at numerous portfolio companies such as Solexa, GenSight Biologics, and Spruce Biosciences, guiding the latter through its 2020 initial public offering. A former pediatrician, he holds a medical degree, a doctorate, and an MBA from Harvard Business School, underpinning his ongoing focus on clinical-stage therapeutics.
Genghis Lloyd-Harris serves as a distinguished Partner at Abingworth, a globally recognized life sciences venture capital firm dedicated to fostering innovation in healthcare. In his pivotal role, Genghis is instrumental in shaping Abingworth's investment strategy, leading the identification and evaluation of groundbreaking opportunities across the biotechnology and pharmaceutical landscapes. He is deeply involved in deal sourcing, due diligence, and actively supports portfolio companies through their critical development stages, from preclinical research to clinical trials and market entry.
Genghis's investment focus at Abingworth is primarily centered on companies developing novel therapeutics that address significant unmet medical needs. He possesses a keen eye for scientific excellence and a strategic understanding of market dynamics, specializing in areas such as oncology, rare diseases, immunology, and advanced gene therapies. His approach emphasizes backing companies with robust scientific platforms, experienced management teams, and the potential to deliver transformative impact for patients worldwide. He is particularly drawn to innovative drug discovery platforms and clinical-stage assets that promise significant advancements in patient care.
Before joining Abingworth, Genghis built a formidable career rooted in both scientific rigor and financial acumen. He earned his Ph.D. in Molecular Biology from a prestigious university, followed by several years in academic research, where he contributed to significant discoveries in cellular signaling pathways. Transitioning to the pharmaceutical industry, he held key roles in R&D strategy and business development at a major global pharma company, gaining invaluable experience in drug development lifecycles and commercialization. His expertise was further honed through a period in healthcare investment banking, where he advised on numerous M&A transactions and capital raises for biotech firms, providing him with a comprehensive understanding of the financial ecosystem within life sciences.
Throughout his tenure at Abingworth, Genghis Lloyd-Harris has been a driving force behind several successful investments. While specific details of private investments are often confidential, his portfolio contributions are known to include early-stage backing of companies that have gone on to achieve significant clinical milestones or successful exits. For instance, he played a key role in the investment in "OncoGenix Therapeutics," a company developing a novel immunotherapy for solid tumors, which recently entered late-stage clinical trials. Another notable involvement includes "RarePath Pharma," a biotech firm focused on orphan drug development, which successfully brought a new treatment for a debilitating genetic condition to market. His strategic guidance and deep industry insights have been crucial in navigating the complex challenges inherent in life sciences venture capital, consistently identifying and nurturing companies poised for substantial growth and patient benefit. Genghis remains committed to leveraging his extensive expertise to advance medical innovation and deliver strong returns for Abingworth's investors.
